Lido Advisors’s Lucid Diagnostics LUCD Stock Holding History

Lido Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$441K	Hold	383,082	–	–	﹤0.01%	1366
2025 Q4	$387K	Hold	383,082	–	–	﹤0.01%	1427
2025 Q3	$387K	Hold	383,082	–	–	﹤0.01%	1351
2025 Q2	$441K	Hold	383,082	–	–	﹤0.01%	1154
2025 Q1	$571K	Buy	383,082 +243,066	+174%	+$292K	﹤0.01%	977
2024 Q4	$115K	Buy	140,016 +40,000	+40%	+$35.3K	﹤0.01%	1435
2024 Q3	$81.5K	Buy	100,016 +32,000	+47%	+$26.2K	﹤0.01%	1409
2024 Q2	$55.8K	Buy	+68,016	New	+$57.7K	﹤0.01%	1374

Other funds holding LUCD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Lido Advisors's LUCD Position: Q1 2026 in Review

Lido Advisors held its Lucid Diagnostics (LUCD) position steady in Q1 2026 at 383,082 shares worth $441K. The position accounts for ﹤0.01% of the portfolio, ranked #1366.

Lido Advisors first reported a position in LUCD in Q2 2024 and has held it in 8 quarters since. The position peaked at $571K in Q1 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

Lido Advisors held 383,082 shares of Lucid Diagnostics worth $441K as of Q1 2026.
Lido Advisors left its Lucid Diagnostics share count unchanged in Q1 2026.
Lucid Diagnostics made up ﹤0.01% of Lido Advisors's portfolio in Q1 2026, its #1366 holding.
Lido Advisors first reported a position in Lucid Diagnostics in Q2 2024 and has held it in 8 quarters since.
Lido Advisors's Lucid Diagnostics position peaked at $571K in Q1 2025.
103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.